文章核心观点 - ADC Therapeutics是一家商业阶段的全球领先和开创性的抗体药物偶联体(ADC)公司 [3] - 公司的CD19定向ADC ZYNLONTA(loncastuximab tesirine-lpyl)已获得FDA加速批准和欧盟条件批准,用于治疗复发或难治性弥漫性大B细胞淋巴瘤 [4] - ZYNLONTA正在与其他药物联合用药和早期治疗线进行开发,公司还有多个ADC处于临床和临前开发阶段 [4] 公司概况 - 公司总部位于瑞士洛桑(Biopôle),在伦敦和新泽西州也有运营 [5] - 公司专注于开发ADC技术,以改变血液恶性肿瘤和实体瘤患者的治疗模式 [3] 财务和运营情况 - 公司将于2024年8月6日召开电话会议和网络直播,报告2024年第二季度的财务业绩和运营更新 [1][2] - 公司正在实施更新后的公司战略,包括提高运营效率、资本部署和投资组合优先级 [6] - 公司预计2024年总运营费用将有所下降,现金储备将持续到2026年中期 [6] - 公司正在实施新的商业销售策略,以提高ZYNLONTA在美国的收入 [6] - 公司的合作伙伴Sobi正在欧洲经济区成功推广ZYNLONTA,以及Overland ADCT BioPharma在中国提交的ZYNLONTA上市申请 [6] - 公司还与三菱化学制药公司等合作伙伴正在推进ZYNLONTA在其他国家的监管审批和商业化 [6] - 公司正在进行多项临床试验,包括LOTIS 5和7、ADCT 601和602,以及早期管线研究项目 [6] - 公司面临一定的财务风险,包括债务融资、限制性条款以及大量现金需求用于偿还债务 [6]

文章核心观点 - 全球多元化专业服务和投资管理公司Colliers完成收购加拿大领先的多学科工程、环境和检验服务公司Englobe的控股权[1] - 此次收购标志着Colliers进入了有吸引力的加拿大工程市场,并增强了其不断发展的工程部门的能力[1] 公司概况 Colliers - Colliers是一家领先的多元化专业服务和投资管理公司[4] - 在68个国家拥有19,000名富有进取心的专业人士[4] - 过去29年里,经验丰富的领导层持有大量内部股权,为股东带来了约20%的年复合投资回报率[4] - 年收入43亿美元,管理资产960亿美元[4] Englobe - Englobe总部位于拉瓦尔,是一家领先的工程和环境服务公司,在加拿大各地拥有广泛的办事处和设施网络[5] - 公司拥有2,800多名员工,包括工程师、专业人士、技术人员和技术支持人员[5] - Englobe提供广泛的服务,包括工程、设计和检验,以及环境咨询和修复[5] - 每年为公共和私营部门客户完成2.5万多个项目[5]

Breakthrough Device Designations are granted by the U.S. FDA to expedite review of promising technologies that address high unmet needs and may improve the lives of people with life-threatening or debilitating conditions REMAIN-1 pivotal study underway to accelerate pathway for weight maintenance indication for Revita®, with anticipated data readouts beginning in Q4 2024 BURLINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company ...

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Getty Realty Corp. (NYSE:GTY) (the "Company") today announced the pricing of an underwritten public offering of 3,500,000 shares of its common stock, sold on a forward basis in connection with the forward sale agreements described below, at a public offering price of $30.10 per share. The forward purchasers (or their affiliates) and the Company have also granted the underwriters of the offering a 30-day option to purchase up to an additional 525,000 shares of comm ...

VANCOUVER, BC, July 30, 2024 /PRNewswire/ -- Siyata Mobile Inc. (Nasdaq: SYTA) ("Siyata" or the "Company"), a global developer and vendor of Push-to-Talk over Cellular (PoC) handsets and accessories, today announced that it will attend APCO 2024, APCO International's Annual Conference & Expo, August 4-7 at the Orange County Convention Center in Orlando, Florida. The Company's products will be on display in a booth hosted by FirstNet, Booth #1313, in the Exhibit Hall. Mr. Marc Seelenfreund, Founder and CEO o ...

文章核心观点 - Centro Benefits Research(Centro)宣布继续扩展其经纪人-承保商API平台,与第二家附属保险承保商Principal Financial Group®建立了RFP(投标请求)和报价集成 [1][2][3] - 这一API连接使Centro和Principal能够无缝交换RFP数据,大幅提高了数据准确性和周转时间,为计划持有人提供更快捷和全面的服务 [2][3] - Centro未来12个月内将与更多附属保险承保商建立API连接,届时将有超过50%的Centro客户的员工福利产品实现全自动化 [5] 公司概况 - Centro Benefits Research是一家附属福利和技术咨询公司,致力于为经纪人和承保商提供最佳客户服务解决方案 [6] - Principal Financial Group®是一家拥有20,000名员工的全球金融公司,为超过62百万客户提供规划、保护、投资和退休服务 [7] - Principal Financial Group®被评为2023年"世界最具道德企业"之一,并入选彭博性别平等指数,被评为"资产管理业最佳工作场所" [7] 行业动态 - Centro与Principal的API集成是推动行业数字化转型的创新举措,有助于提高客户服务效率 [3][4] - 行业正朝着更加自动化和数字化的方向发展,这有利于提升整个价值链的业务和运营效益 [3][5]

BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $175.0 million, before deducting placement agent fees and ...

SUNNYVALE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has submitted a 510(k) for approval of its patented Morph® DNA™ Steerable Introducer Sheath. This product family is intended to provide a pathway through which medical instruments, such as balloon dilatation catheters, guidewires, or other therapeutic devices, may be introduced into the peripher ...

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2024 financial results on Tuesday, August 6th, before the financial markets open.   Management will host a conference call and webcast with the investment community at 8:30 am ( ...

LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BI796eccb31 ...